#11497
Re: Análisis de Pharmamar (PHM), antigua Zeltia
Vamos a pensar que estamos en el punto de inflexión después de los resultados de 2023. Ahora solo tienen que quedar noticias buenas...Se presentará dentro de mes y medio en el AACR, par el del punto de control:
https://www.abstractsonline.com/pp8/#!/20272/presentation/7433
“the lurbinectedin-induced multimodal immune modulation in SCLC leading to a dramatic anti-tumor activity accompanied by the establishment of a strong anti-tumor immune microenvironmen”
“our preclinical data provide a strong rationale for combining this regimen with inhibitors of the PD-L1 pathway”
https://www.abstractsonline.com/pp8/#!/20272/presentation/7433
“the lurbinectedin-induced multimodal immune modulation in SCLC leading to a dramatic anti-tumor activity accompanied by the establishment of a strong anti-tumor immune microenvironmen”
“our preclinical data provide a strong rationale for combining this regimen with inhibitors of the PD-L1 pathway”